Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.

医学 抗合成酶综合征 间质性肺病 钙调神经磷酸酶 四分位间距 他克莫司 自身抗体 内科学 多发性肌炎 皮肌炎 胃肠病学 队列 免疫学 肺 移植 抗体
作者
Ane Labirua-Iturburu Ruiz,Albert Selva-O’Callaghan,Xavier Martínez‐Gómez,Ernesto Trallero Araguás,Moisés Labrador‐Horrillo,Miquel Vilardell
出处
期刊:PubMed [National Institutes of Health]
卷期号:31 (3): 436-9 被引量:76
链接
标识
摘要

OBJECTIVES: The aim of this paper is to assess the effect of calcineurin inhibitors (tacrolimus or cyclosporine) for treating patients with interstitial lung disease (ILD) associated with antisynthetase autoantibodies. METHODS: Sixty patients with antisynthetase autoantibodies were identified in our myositis cohort of 179 patients. The medical records of 15 patients with antisynthetase autoantibody-associated ILD treated with tacrolimus/cyclosporine (11 for refractory disease and 4 as first-line therapy) between 1980 and 2011 were retrospectively reviewed. Serial pulmonary function tests were used to assess the clinical response. Qualitative data are presented as a number and percentage, and quantitative data as the median and interquartile range (IQR). RESULTS: Patients were classified as having probable or definite idiopathic inflammatory myopathy (8 dermatomyositis and 4 polymyositis), and pure interstitial lung disease (3 cases). The 15 patients had received tacrolimus/cyclosporine for an average of 19 (IQR 14-30) months. Median age at onset of ILD was 42.3 (IQR 32.4-56.8) years and median duration of lung disease before administration of calcineurin inhibitors was 11 (IQR: 5-49) months. Median duration of follow-up was 24 (IQR 12-32) months. Thirteen patients had anti-histidyl-transfer RNA synthetase autoantibody (anti-Jo-1) and two had anti-alanyl-transfer RNA synthetase autoantibody (anti-PL-12). A more than 10% increase in FVC or stabilisation was observed in 13 (87%; 95%CI 56-98) patients who received calcineurin inhibitors (9 [81%] refractory cases and 4 [100%] as first-line therapy). CONCLUSIONS: Calcineurin inhibitors seem to be a good therapeutic option for managing ILD associated with antisynthetase autoantibodies, not only in refractory cases, but also as first-line treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2的应助被action采纳,获得10
2秒前
ding的应助被小陈采纳,获得10
2秒前
执着的尔容完成签到,获得积分10
6秒前
研友_VZG7GZ的应助被863采纳,获得10
7秒前
Bright完成签到 ,获得积分10
8秒前
秋风的应助被DW采纳,获得10
10秒前
Pursue。完成签到,获得积分10
10秒前
12秒前
TPolymer完成签到,获得积分10
15秒前
脑洞疼的应助被扶竹苏春采纳,获得10
16秒前
化学废材完成签到,获得积分10
17秒前
CodeCraft的应助被hyska采纳,获得10
18秒前
含蓄书桃发布了新的文献求助10
19秒前
19秒前
20秒前
21秒前
健康的魔镜完成签到 ,获得积分10
23秒前
华无剑的应助被DW采纳,获得10
23秒前
24秒前
小乐乐完成签到 ,获得积分10
24秒前
斯文败类的应助被淡淡青枫采纳,获得10
26秒前
27秒前
山海不远发布了新的文献求助10
28秒前
uniphoton完成签到,获得积分10
29秒前
fatal发布了新的文献求助10
31秒前
111发布了新的文献求助10
31秒前
粥粥粥完成签到 ,获得积分10
32秒前
ding的应助被木木采纳,获得10
33秒前
叶上初阳完成签到,获得积分0
33秒前
干咸鱼叔叔完成签到,获得积分10
34秒前
GoGoGo完成签到,获得积分10
35秒前
hitech的应助被fatal采纳,获得10
37秒前
科研通AI6.2的应助被山海不远采纳,获得30
38秒前
含蓄书桃完成签到 ,获得积分10
38秒前
spark发布了新的文献求助10
39秒前
Crazy鑫完成签到,获得积分10
41秒前
42秒前
43秒前
快乐鼠完成签到,获得积分10
45秒前
46秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576127
关于积分的说明 21845709
捐赠科研通 7786389
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482196